WT1 and myelodysplastic syndrome: Whole genome sequencing techniques have been able to establish that the progression of MDS to AML is defined by the persistence of a founder clone, and the emergence or growth of at least one subclone, carrying new mutations (mostly FLT3, NPM1, NRAS, PTPN11, WT1, IDH1 and IDH2).